Sequential Complement and BAFF/APRIL Blockade Reduces Proteinuria, Stabilizes Kidney Function in Aggressive IgAN/IgAVN

IgA nephropathy (IgAN) and IgA vasculitis nephritis (IgAVN) are severe kidney diseases marked by significant glomerular inflammation, extensive extracapillary proliferation, and rapid decline in renal function. Despite growing understanding of their shared pathogenic mechanisms, optimal treatment strategies remain elusive. Current approaches often fall short in halting disease progression, particularly in rapidly progressive forms. Both conditions involve mesangial IgA deposition, triggering complement activation (primarily via the alternative pathway) and are mediated by B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), highlighting these as key therapeutic targets.

This case report describes two patients presenting with rapidly progressive crescentic disease: one with primary IgAN and the other with IgAVN. Both individuals received a multi-pathway targeted therapy consisting of sequential complement inhibition combined with BAFF/APRIL blockade. The specific agents, doses, and durations of treatment are not detailed in the abstract. The primary endpoints observed were changes in proteinuria levels and the stability of kidney function during follow-up, aiming to assess the clinical efficacy of this combined therapeutic approach in aggressive forms of these nephropathies.

Both patients demonstrated significant clinical improvement following the sequential multi-pathway therapy. They experienced substantial reductions in proteinuria, indicating a positive impact on glomerular integrity and inflammation. Crucially, kidney function was observed to stabilize during the follow-up period, halting the rapid decline characteristic of their aggressive disease forms. This suggests the combined intervention effectively mitigated the progressive renal damage. While specific quantitative data for proteinuria reduction or glomerular filtration rate (GFR) stabilization are not provided, the abstract highlights the clinical significance of these improvements. The findings underscore the potential of targeting multiple pathogenic pathways simultaneously.

Both patients showed substantial reductions in proteinuria and stabilization of kidney function during follow-up.